semaglutide rate of weight loss results after 8 months on Semaglutide weight loss dosage chart
Description
Semaglutide was approved in 2017 as Ozempic for diabetes, and in 2021 as Wegovy for obesity
Enhances overall metabolic efficiency
Long-term use of semaglutide carries real risks: GI issues, gallbladder problems, possible pancreatitis, and cardiovascular concerns
Ozempic can lower blood pressure in modest amounts, which can be an added bonus if you have obesity and hypertension
Yes, Wegovy can be used in people with type 2 diabetes, and it is one of the qualifying weight-related comorbidities that may make you eligible for treatment with a BMI of 27 or above
Among these, pioglitazone and liraglutide seem to improve some histological features of NASH but have no clear effect on fibrosis
